US Pharma MarketingBeOne culls five cancer programs and an autoimmune Phase 2
BeOne Medicines has greatly expanded its pipeline over the years, bringing 18 new molecular entities to the fore across 2024 and 2025. But that also means the drugmaker will likely cull more experimental medicines as part of the industry Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling…
BeOne Medicines has greatly expanded its pipeline over the years, bringing 18 new molecular entities to the fore across 2024 and 2025. But that also means the drugmaker will likely cull more experimental medicines as ...
Source: Endpoints News